Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson(Genomics (United Kingdom)), Randy D. Gascoyne(BC Cancer Agency), Wing C. Chan(Ontario Institute for Cancer Research), Kerry J. Savage(Spinal Cord Injury BC), David W. Scott(BC Cancer Agency), Dennis D. Weisenburger(University of Nebraska Medical Center), Joseph M. Connors, Louis M. Staudt(National Cancer Institute), Laurie H. Sehn(BC Cancer Agency), Susana Ben‐Neriah(Apple (Israel)), Andreas Rosenwald(Comprehensive Cancer Center Mainfranken), Elı́as Campo(Hospital Clínic de Barcelona), Patrick Brunhoeber(Apple (Israel)), Paul N. Meyer(Apple (Israel)), Georg Lenz(Charité - Universitätsmedizin Berlin), Christian Steidl(University of British Columbia), Javeed Iqbal(University of Nebraska Medical Center), Carlo Valentino(Apple (Israel)), Graham W. Slack(BC Cancer Agency), James R. Cook(Cleveland Clinic), German Ott(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Rita M. Braziel(Oregon Health & Science University), Jan Delabie, George W. Wright(National Cancer Institute), Elaine S. Jaffe(National Cancer Institute), King Tan(Apple (Israel)), Christina Holcroft(Apple (Israel)), Raymond R. Tubbs(Cleveland Clinic), Sanja Rogić(Apple (Israel)), Thomas M. Grogan, Lisa M. Rimsza(Banner - University Medical Center Tucson)
Cited by 971
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k